Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated October 1, 2024 (before its estimated November 28, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary endpoints: 1 to 7
    • Eligibility criteria shortened, about 63 words
    • Secondary endpoints: 2 to 19
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 3, 2024 to Jul 11, 2024
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.
Trial Details
NCT Number NCT06263998
Lead Sponsor Huons Co., Ltd.
Conditions
(from sponsor)		 Xerophthalmia
Related terms Xerophthalmia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov